Similar and substantial reductions in hot flashes and night sweats in recently postmenopausal women were observed with lower than conventional doses of oral or transdermal estrogen, a recent study found. The Kronos Early Estrogen Prevention Study included 727 women (aged 42 to 58 years) randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n=230) or transdermal estradiol (t-E2) 50[mu]g (n=225), or placebos (PBOs; n=275). Menopausal symptoms were recorded at screening and at 6, 12, 24, 36, and 48 months postrandomization. Researchers found:
- Moderate to severe hot flashes and night sweats were significantly reduced by 6 months in women randomized to either active hormone compared with PBO.
- These reductions were sustained during 4 years.
- Insomnia and irritability decreased from baseline to 6 months postrandomization in all groups.
- There was an intermittent reduction in insomnia in both active treatment arms vs PBO.
- Symptom relief for active treatment vs PBO was not significantly modified by body mass index (BMI) or race/ethnicity.
Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: The Kronos Early Estrogen Prevention Study. [Published online ahead of print October 24, 2016]. Menopause. doi:10.1097/GME.0000000000000756.
This Week's Must Reads
Must Reads in Menopause
Menopause Symptom Burden and Chronic Pain, Menopause; ePub 2019 Mar 4; Gibson, et al
Trends in Menopausal Hormone Therapy, Menopause; ePub 2018 Dec 21; Crawford, et al
Chronic Disease Risk with Vaginal Estrogen Use, Menopause; ePub 2018 Dec 17; Bhupathiraju, et al
Sleep Disturbance After Surgical Menopause, Menopause; ePub 2018 Nov 12; Cho, Kim, et al
Cardiac Autonomic Function in Midlife Women, Menopause; ePub 2018 Jun 18; Fu, et al